{"id":"lavasept-0-04","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation"},{"rate":null,"effect":"Contact dermatitis"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lavasept contains polyhexamethylene biguanide (PHMB), a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and denatures proteins, leading to rapid microbial death. It is formulated as a 0.04% solution for topical use in infection control and wound care settings. The mechanism provides fast-acting antimicrobial activity with low systemic toxicity due to minimal skin penetration.","oneSentence":"Lavasept is an antimicrobial skin antiseptic that kills bacteria and other microorganisms through oxidative damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:44.764Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Skin antisepsis and infection control in wound care"},{"name":"Perioperative skin preparation"}]},"trialDetails":[{"nctId":"NCT06338163","phase":"PHASE4","title":"Polihexanide SSIs Measures Bundle (PSMB) During Enhanced Recovery After Major Digestive Surgery","status":"NOT_YET_RECRUITING","sponsor":"Marco Catarci","startDate":"2024-07-01","conditions":"Surgical Site Infection, Surgical Procedures, Operative","enrollment":2000},{"nctId":"NCT04055233","phase":"PHASE3","title":"Reduction of Postoperative Wound Infections by Antiseptica?","status":"COMPLETED","sponsor":"Johannes Lauscher","startDate":"2015-02-01","conditions":"Surgical Site Infection","enrollment":456},{"nctId":"NCT02506257","phase":"PHASE1","title":"Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects","status":"COMPLETED","sponsor":"SIFI SpA","startDate":"2015-11","conditions":"Acanthamoeba Keratitis","enrollment":90},{"nctId":"NCT01153620","phase":"PHASE4","title":"The Antiseptic Efficacy and Tolerability of Lavasept® 0.04% on Acute Traumatic Wounds","status":"COMPLETED","sponsor":"B. Braun Ltd. Centre of Excellence Infection Control","startDate":"2010-08","conditions":"Wounds","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lavasept 0.04%","genericName":"Lavasept 0.04%","companyName":"B. Braun Ltd. Centre of Excellence Infection Control","companyId":"b-braun-ltd-centre-of-excellence-infection-control","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lavasept is an antimicrobial skin antiseptic that kills bacteria and other microorganisms through oxidative damage. Used for Skin antisepsis and infection control in wound care, Perioperative skin preparation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}